Luoxin Pharmaceuticals Group Stock Co., Ltd. Class A

As of June 30, 2026, Luoxin Pharmaceuticals Group Stock Co., Ltd. Class A carries a market capitalization of 4.18B, placing it among publicly traded companies globally. Its enterprise value stands at 4.55B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Luoxin Pharmaceuticals Group Stock Co., Ltd. Class A has 1.09B shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.81, and the price-to-book ratio stands at 3.71.

These figures are as of June 30, 2026. The EV/Sales ratio of 1.98 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 4.55B versus a market cap of 4.18B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Luoxin Pharmaceuticals Group Stock Co., Ltd. Class A maintains a current ratio of 0.79, meaning it holds 0.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 106.25, indicating elevated leverage, while an interest coverage ratio of -5.15 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Luoxin Pharmaceuticals Group Stock Co., Ltd. Class A posted a negative return on equity (ROE) of -19.79, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -6.48, reflecting losses generated across the asset base. The company generates approximately 758,818.92 in revenue per employee across its workforce of 3,020.50, a quick read on workforce productivity versus industry peers. Inventory turnover of 2.53 indicates how many times Luoxin Pharmaceuticals Group Stock Co., Ltd. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Luoxin Pharmaceuticals Group Stock Co., Ltd. Class A recorded an income tax benefit of -1.63M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -246.64M and -249.53M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 23, 2026, Luoxin Pharmaceuticals Group Stock Co., Ltd. Class A's stock has declined approximately 21.49% over the past 52 weeks. The 50-day moving average sits at 4.83, while the 200-day moving average is 4.78.

Over the twelve months ended June 30, 2026, Luoxin Pharmaceuticals Group Stock Co., Ltd. Class A generated 2.29B in revenue and converted that into -249.53M in net income, yielding earnings per share of -0.23. EBITDA reached -254.14M, while operating income came in at -74.21M.

As of June 30, 2026, Luoxin Pharmaceuticals Group Stock Co., Ltd. Class A holds 983.06M in cash and equivalents against 1.28B in total debt, resulting in a net debt position of 140.40M. Total book value stands at 1.13B, with working capital of -488.68M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Luoxin Pharmaceuticals Group Stock Co., Ltd. Class A posted a gross margin of 54.47, reflecting its pricing power and cost economics. The operating margin of -3.24 and net profit margin of -10.89 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Luoxin Pharmaceuticals Group Stock Co., Ltd. Class A paid dividends of 0.04 per share. The dividend payout ratio of -17.30 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 3.22, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Luoxin Pharmaceuticals Group Stock Co., Ltd. Class A shareholders.

Luoxin Pharmaceuticals Group Stock Co., Ltd. Class A's most recent stock split took place on September 23, 2019 with a 10:17 split ratio.

As of June 30, 2026, Luoxin Pharmaceuticals Group Stock Co., Ltd. Class A has an Altman Z-Score of 1.37, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.